skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Suppression of cytochrome P450 3A protein levels by proteasome inhibitors.

Journal Article · · Journal of pharmacology and experimental therapeutics
 [1];  [2];  [3];  [1];  [4];  [5]
  1. BATTELLE (PACIFIC NW LAB)
  2. Wayne State University
  3. ASSOC WESTERN UNIVERSITY
  4. Missouri, Univ Of - Kansas Cit
  5. OFFICE OF FELLOWSHIP PROGRAMS

We have previously reported that CYP3A cross-links with polyubiquitinated proteins in microsomes from nicardipine-treated rats in a process that is distinct from classical polyubiquitination. To further examine the role of the proteasome in CYP3A degradation, we investigated the effects of proteasome inhibitors lactacystin, MG132, proteasome inhibitor 1, and hemin in primary cultures of rat and human hepatocytes. With the exception of hemin, these agents increased the total pool of ubiquitinated proteins in microsomes isolated from rat hepatocytes, indicating that lactacystin, MG132, and proteasome inhibitor 1 effectively inhibited the proteasome in these cells. All four agents caused a reduction in the amount of the major approximately 55-kDa CYP3A band, opposite to what would be expected if the ubiquitin-proteasome pathway degraded CYP3A. Only hemin treatment caused an increase in high molecular mass (HMM) CYP3A bands. Because hemin treatment did not alter levels of ubiquitin in CYP3 A immunoprecipitates, the HMM CYP3A bands formed in response to hemin treatment clearly were not due to proteasome inhibition. Rather, because hemin treatment also caused an increase in HMM CYP3A in the detergent-insoluble fraction of the 10,000g pellet, the HMM CYP3A seems to represent a large protein complex that is unlikely to primarily represent ubiquitination.

Research Organization:
Pacific Northwest National Lab., Richland, WA (US) (US)
Sponsoring Organization:
US Department of Energy (US)
DOE Contract Number:
AC06-76RL01830
OSTI ID:
15006020
Report Number(s):
PNWD-SA-6057; TRN: US200402%%311
Journal Information:
Journal of pharmacology and experimental therapeutics, Vol. 305, Issue 3; Other Information: PBD: 1 Jun 2003
Country of Publication:
United States
Language:
English

Similar Records

Cytochrome P450 3A Conjugation to Ubiquitin in a Process Distinct from Classical Ubiquitination Pathway
Journal Article · Sat Dec 01 00:00:00 EST 2001 · Molecular Pharmacology · OSTI ID:15006020

Effect of proteasome inhibition on toxicity and CYP3A23 induction in cultured rat hepatocytes: Comparison with arsenite
Journal Article · Fri Dec 15 00:00:00 EST 2006 · Toxicology and Applied Pharmacology · OSTI ID:15006020

Interactions of phospholipase D and cytochrome P450 protein stability
Journal Article · Sun Aug 01 00:00:00 EDT 2004 · Biochemical Pharmacology · OSTI ID:15006020